文献速递呼吸道感染呼吸危重症与机械通气

呼吸道上皮细胞对SARS-CoV-2的应答与COVID-19分期治疗启示

Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19.
PubMed 文献 · Thorax · 2021-08-17

本综述以肺上皮为线索,对比传导气道与气体交换区的细胞组成和先天免疫差异,指出鼻内纤毛细胞是SARS-CoV-2感染、复制和释放的主要靶细胞,肺泡II型上皮细胞则是肺泡感染的主要靶细胞;上气道免疫应答受抑或激活不全,无症状者仍可排毒传染;肺泡感染可引发高炎症状态,是重症治疗靶点,且因肺泡II型细胞兼有前体细胞属性,肺内修复结局不一,可能遗留瘢痕和长期后遗症。

要点

  • 鼻内纤毛细胞是SARS-CoV-2感染、复制和释放的主要靶细胞,感染后纤毛脱落致黏液纤毛清除功能受损。
  • 上气道对SARS-CoV-2的先天免疫应答受抑或激活不全,无症状者仍可有产毒性感染并传染他人。
  • 肺泡II型上皮细胞是气体交换区主要靶细胞,细胞死亡和显著先天免疫应答参与肺泡损伤和ARDS。

核心结论

  • COVID-19不同临床阶段的有效治疗取决于感染部位和范围,传导气道与气体交换区细胞组成和先天免疫不同,提示应选用不同治疗药物。

研究设计与样本

  • 本文为综述,围绕肺上皮推进COVID-19病程理解并讨论治疗选择,重点对比传导气道与肺气体交换区两个感染部位。

主要发现

  • 鼻内纤毛细胞是SARS-CoV-2感染、复制和释放的主要靶细胞,感染细胞脱落纤毛使黏液纤毛清除功能受损。
  • 证据进一步提示上气道对SARS-CoV-2感染的先天免疫应答受抑或激活不全。
  • 无症状个体仍可有产毒性病毒感染并传染他人。
  • 肺泡II型上皮细胞是肺气体交换区主要靶细胞,感染中细胞死亡和显著先天免疫应答可能参与肺泡损伤和ARDS。
  • 肺泡感染可促发高炎症状态,是重症COVID-19多种治疗的靶点;因肺泡II型细胞也是肺泡上皮前体细胞,肺内疾病消退结局不一,可能包括瘢痕和长期后遗症。

临床怎么用

  • 按感染部位和临床阶段选择治疗方向:上气道与肺泡区细胞组成和先天免疫不同,提示使用不同治疗药物。
  • 重症COVID-19针对高炎症状态进行治疗。
  • 关注上气道黏液纤毛清除受损及无症状者仍可传染的防控意义。
  • 随访肺泡感染后修复结局,警惕瘢痕和长期后遗症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 has different clinical stages, and effective therapy depends on the location and extent of the infection. The purpose of this review is to provide a background for understanding the progression of the disease throughout the pulmonary epithelium and discuss therapeutic options. The prime sites for infection that will be contrasted in this review are the conducting airways and the gas exchange portions of the lung. These two sites are characterised by distinct cellular composition and innate immune responses, which suggests the use of distinct therapeutic agents. In the nose, ciliated cells are the primary target cells for SARS-CoV-2 viral infection, replication and release. Infected cells shed their cilia, which disables mucociliary clearance. Evidence further points to a suppressed or incompletely activated innate immune response to SARS-CoV-2 infection in the upper airways. Asymptomatic individuals can still have a productive viral infection and infect others. In the gas exchange portion of the lung, the alveolar type II epithelial cell is the main target cell type. Cell death and marked innate immune response during infection likely contribute to alveolar damage and resultant acute respiratory distress syndrome. Alveolar infection can precipitate a hyperinflammatory state, which is the target of many therapies in severe COVID-19. Disease resolution in the lung is variable and may include scaring and long-term sequalae because the alveolar type II cells are also progenitor cells for the alveolar epithelium.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Bridges JP, Vladar EK, Huang H, et al. Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax. 2021. PMID: 34404754. doi:10.1136/thoraxjnl-2021-217561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。